Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Perinatol ; 33(1): 83-5, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23269232

ABSTRACT

Neonatal hemochromatosis (NH) is a rare and severe liver disease of mainly intra-uterine onset, characterized by neonatal liver failure, hepatic and extrahepatic iron accumulation. This leads to an altered iron metabolism with resulting siderosis. The disease represents the most common cause of liver failure in neonates and is also the most common indication for neonatal liver transplantation. We present a case of a newborn diagnosed with NH and life threatening liver failure. Initial treatment consisted of chelation therapy and antioxidants, but lack of laboratory and clinical improvement led to an exchange transfusion followed by the singular substitution of intravenous immunoglobulin (IVIG). Both, exchange transfusion and IVIG were tolerated well and led to an improvement of the general condition of the patient and recovery of liver synthetic function. The subsequent favorable course of the disease is described in this case report.


Subject(s)
Exchange Transfusion, Whole Blood , Hemochromatosis/therapy , Immunization, Passive , Liver Failure, Acute/therapy , Bilirubin/blood , Blood Coagulation Tests , Combined Modality Therapy , Female , Ferritins/blood , Fetal Growth Retardation/diagnosis , Hemochromatosis/blood , Hemochromatosis/diagnosis , Humans , Infant, Newborn , Infant, Small for Gestational Age , Liver Failure, Acute/blood , Liver Failure, Acute/diagnosis , Liver Function Tests , Thrombocytopenia/blood , Thrombocytopenia/diagnosis , Thrombocytopenia/therapy , Treatment Outcome
2.
Transpl Infect Dis ; 14(6): 589-94, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23013490

ABSTRACT

BACKGROUND: For children with hemato-oncologic diseases, especially after hematopoietic stem cell transplantation (HSCT), the risk for developing complications related to pandemic influenza A (H1N1) 2009 (pH1N1) infection is largely unknown. METHODS: A retrospective chart study was performed of pH1N1 cases diagnosed between October 2009 to January 2010 in the hemato-oncologic unit of the University Children's Hospital of Düsseldorf, Germany. FINDINGS: In total, 21 children were diagnosed with laboratory-confirmed pH1N1; in 16 patients with malignancies (acute leukemia 7, lymphoma 4, solid tumors 2, others 3) and in 5 with benign hematologic disorders. Five patients had undergone prior HSCT, although 1 patient was diagnosed during conditioning therapy with high-dose chemotherapy in preparation for haploidentical HSCT. Most frequent symptoms were fever (>38.5°C) and cough (in 100%), and rhinorrhea (57%). The 2 patients acquiring pH1N1 infection under high-dose or intensive chemotherapy did not require intensive care or mechanical ventilation, and both recovered under antiviral therapy. Oseltamivir was administered to 11 patients; in 1 patient, therapy was switched, on a compassionate-use basis, to intravenous zanamivir because of lack of clinical improvement after oseltamivir therapy. Complications were hospitalization (19%), demand of oxygen supplementation, delay/interruption of antineoplastic therapy, and prolonged administration of antibiotics and antipyretics. CONCLUSION: In the investigated patient population, pH1N1 was mild in most cases, but was associated with substantial morbidity in a proportion of patients and led to interruption and delay in anticancer treatment.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/virology , Neoplasms/complications , Pandemics , Adolescent , Antineoplastic Agents/therapeutic use , Antiviral Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Immunocompromised Host , Infant , Influenza, Human/drug therapy , Male , Oseltamivir/therapeutic use , Young Adult
3.
Klin Padiatr ; 224(3): 160-5, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22504775

ABSTRACT

Despite the implementation of new antifungal drugs, invasive aspergillosis (IA) still remains a considerable challenge in pediatric oncology with a severe mortality. Prophylactic and therapeutic measurement have to be evaluated in these rare but poor prognostic patients. Therefore the entire group of patients at risk of developing IA has to be defined before cooperative prospective trials. In a retrospective analysis including all our patients with malignancies we looked for patients with proven/probable IA. Cases of the period from 2003 to 2008 were analyzed in detail.In the period between 2003 to 2008 24 of 755 patients were affected by proven/ probable IA. Compared to former studies incidence increased from 1.3%in 1980 to 3.4% in 2008. AML patients with or without allogeneic/haploidentical stem cell transplantation were at highest risk (24% and 25% respectively, in comparison to 1% in ALL-patients). Survival after 2 years was 50% for patients with AML and IA. In patients with high risk to develop IA the effect of intensified, intravenous antimycotic prophylaxis has to be proven prospectively in a cooperative and randomized setting.


Subject(s)
Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Invasive Pulmonary Aspergillosis/drug therapy , Opportunistic Infections/drug therapy , Pyrimidines/therapeutic use , Triazoles/therapeutic use , Administration, Oral , Adolescent , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Infusions, Intravenous , Invasive Pulmonary Aspergillosis/mortality , Invasive Pulmonary Aspergillosis/prevention & control , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/therapy , Male , Opportunistic Infections/mortality , Opportunistic Infections/prevention & control , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Prognosis , Retrospective Studies , Survival Rate , Voriconazole
5.
New York; New York Academy of Sciences; 1994. 258 p. ilus, tab, graf.(Annals of the New York Academy, 708).
Monography in English | MINSALCHILE | ID: biblio-1541207
SELECTION OF CITATIONS
SEARCH DETAIL
...